
Bloomberg · Feb 23, 2026 · Collected from RSS
Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 million in an initial public offering, as listing activity in the sector picks up sharply.